Literature DB >> 21131916

Progressive multifocal leukoencephalopathy and other forms of JC virus disease.

Bruce J Brew1, Nicholas W S Davies, Paola Cinque, David B Clifford, Avindra Nath.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain caused by the JC virus (JCV). PML usually occurs via reactivation of JCV when an immune system becomes compromised. A diagnosis of PML is normally made on the basis of distinguishing neurological features at presentation, characteristic brain MRI changes and the presence of JCV DNA in cerebrospinal fluid. PML has a 3 month mortality rate of 20-50%, so prompt intervention is essential. Currently, reconstitution of the immune system affords the best prognosis for this condition. When PML is first suspected, and where possible, immunosuppressant or immunomodulatory therapy should be suspended or reduced. If PML is associated with a protein therapy that has a long half-life the use of plasma exchange to accelerate the removal of the drug from the circulation may aid the restoration of immune system function. Rapid improvements in immune function, however, might lead to transient worsening of the disease. In this Review, we critically appraise the controversies surrounding JCV infection, and provide practical management guidelines for PML.

Entities:  

Mesh:

Year:  2010        PMID: 21131916     DOI: 10.1038/nrneurol.2010.164

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  127 in total

1.  Remission of AIDS-associated progressive multifocal leukoencephalopathy after cidofovir therapy.

Authors:  A M Brambilla; A Castagna; R Novati; P Cinque; M R Terreni; M C Moioli; A Lazzarin
Journal:  J Neurol       Date:  1999-08       Impact factor: 4.849

2.  Interferon- alpha and - beta restrict polyomavirus JC replication in primary human fetal glial cells: implications for progressive multifocal leukoencephalopathy therapy.

Authors:  Juliene K G Co; Saguna Verma; Ulziijargal Gurjav; Laarni Sumibcay; Vivek R Nerurkar
Journal:  J Infect Dis       Date:  2007-07-20       Impact factor: 5.226

3.  Asymptomatic reactivation of JC virus in patients treated with natalizumab.

Authors:  Clemens Warnke; Ortwin Adams; Bernd C Kieseier
Journal:  N Engl J Med       Date:  2009-12-17       Impact factor: 91.245

4.  Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy.

Authors:  L Chang; T Ernst; C Tornatore; H Aronow; R Melchor; I Walot; E Singer; M Cornford
Journal:  Neurology       Date:  1997-04       Impact factor: 9.910

Review 5.  Role of the environment in the transmission of JC virus.

Authors:  Sílvia Bofill-Mas; Rosina Girones
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

6.  Detection of JC virus DNA in the peripheral blood leukocytes of HIV-infected patients.

Authors:  V Dubois; M E Lafon; J M Ragnaud; J L Pellegrin; F Damasio; C Baudouin; V Michaud; H J Fleury
Journal:  AIDS       Date:  1996-04       Impact factor: 4.177

7.  Cidofovir treatment of progressive multifocal leukoencephalopathy in a patient receiving highly active antiretroviral therapy.

Authors:  R R Razonable; A J Aksamit; A J Wright; J W Wilson
Journal:  Mayo Clin Proc       Date:  2001-11       Impact factor: 7.616

8.  Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient.

Authors:  F Bernal-Cano; J T Joseph; I J Koralnik
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

9.  Progressive multifocal leukoencephalopathy: diffusion-weighted imaging and pathological correlations.

Authors:  M Bergui; G B Bradac; K K Oguz; A Boghi; C Geda; G Gatti; D Schiffer
Journal:  Neuroradiology       Date:  2003-10-31       Impact factor: 2.804

10.  Identification and characterization of mefloquine efficacy against JC virus in vitro.

Authors:  Margot Brickelmaier; Alexey Lugovskoy; Ramya Kartikeyan; Marta M Reviriego-Mendoza; Norm Allaire; Kenneth Simon; Richard J Frisque; Leonid Gorelik
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191

View more
  93 in total

1.  Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases.

Authors:  A Bharat; F Xie; J W Baddley; T Beukelman; L Chen; L Calabrese; E Delzell; C G Grijalva; N M Patkar; K Saag; K L Winthrop; J R Curtis
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-04       Impact factor: 4.794

2.  JC virus promoter/enhancers contain TATA box-associated Spi-B-binding sites that support early viral gene expression in primary astrocytes.

Authors:  Leslie J Marshall; Lisa D Moore; Matthew M Mirsky; Eugene O Major
Journal:  J Gen Virol       Date:  2011-11-09       Impact factor: 3.891

Review 3.  Progressive multifocal leukoencephalopathy: clinical and molecular aspects.

Authors:  Eleonora Tavazzi; Martyn K White; Kamel Khalili
Journal:  Rev Med Virol       Date:  2011-09-21       Impact factor: 6.989

4.  Analysis of JC virus DNA replication using a quantitative and high-throughput assay.

Authors:  Jong Shin; Paul J Phelan; Panharith Chhum; Nazym Bashkenova; Sung Yim; Robert Parker; David Gagnon; Ole Gjoerup; Jacques Archambault; Peter A Bullock
Journal:  Virology       Date:  2014-08-24       Impact factor: 3.616

5.  Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.

Authors:  Ivan Jelcic; Benoit Combaluzier; Ilijas Jelcic; Wolfgang Faigle; Luzia Senn; Brenda J Reinhart; Luisa Ströh; Roger M Nitsch; Thilo Stehle; Mireia Sospedra; Jan Grimm; Roland Martin
Journal:  Sci Transl Med       Date:  2015-09-23       Impact factor: 17.956

6.  Prophylactic antiepileptic treatment reduces seizure frequency in natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Robert Hoepner; Stefanie Dahlhaus; Susanne Kollar; Barbara Zurawski; Andrew Chan; Ingo Kleiter; Ralf Gold; Kerstin Hellwig
Journal:  Ther Adv Neurol Disord       Date:  2014-01       Impact factor: 6.570

7.  Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.

Authors:  Emanuelle Bellaguarda; Kian Keyashian; Joel Pekow; David T Rubin; Russell D Cohen; Atsushi Sakuraba
Journal:  Clin Gastroenterol Hepatol       Date:  2015-05-19       Impact factor: 11.382

8.  Immune suppression of JC virus gene expression is mediated by SRSF1.

Authors:  Rahsan Sariyer; Francesca Isabella De-Simone; Jennifer Gordon; Ilker Kudret Sariyer
Journal:  J Neurovirol       Date:  2016-03-07       Impact factor: 2.643

9.  Dihydropyrimidinones and -thiones with improved activity against human polyomavirus family members.

Authors:  Alexandra Manos-Turvey; Hiba A Al-Ashtal; Patrick G Needham; Caroll B Hartline; Mark N Prichard; Peter Wipf; Jeffrey L Brodsky
Journal:  Bioorg Med Chem Lett       Date:  2016-08-25       Impact factor: 2.823

10.  Complete genome sequence of a polyomavirus isolated from horses.

Authors:  Randall W Renshaw; Annabel G Wise; Roger K Maes; Edward J Dubovi
Journal:  J Virol       Date:  2012-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.